ACM
AZN icon

Armbruster Capital Management’s AstraZeneca AZN Stock Holding History

Armbruster Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-150
Closed -$9K – 274
2017
Q1 		$9K Hold
150
– – 0.01% 216
2016
Q4 		$8K Hold
150
– – ﹤0.01% 221
2016
Q3 		$10K Hold
150
– – 0.01% 211
2016
Q2 		$9K Hold
150
– – 0.01% 214
2016
Q1 		$8K Hold
150
– – 0.01% 249
2015
Q4 		$10K Buy
+150
New +$9.83K 0.01% 231

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Armbruster Capital Management's AZN Position: Q2 2017 in Review

Armbruster Capital Management sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 150 shares — an estimated $9K sold.

Armbruster Capital Management first reported a position in AZN in Q4 2015 and held it in 6 quarters. The position peaked at $10K in Q3 2016. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

  • Armbruster Capital Management reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
  • Armbruster Capital Management sold 150 AstraZeneca shares in Q2 2017, an estimated $9K.
  • Armbruster Capital Management first reported a position in AstraZeneca in Q4 2015 and held it in 6 quarters.
  • Armbruster Capital Management's AstraZeneca position peaked at $10K in Q3 2016.
  • 466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Armbruster Capital Management's 13F filing for Q2 2017, filed 1 Aug 2017.